Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;14 Suppl 6(Suppl 6):S13.
doi: 10.1186/1471-2334-14-S6-S13. Epub 2014 Sep 19.

HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective

Lars Peters, Amanda Mocroft, Jens Lundgren, Daniel Grint, Ole Kirk, Jürgen Rockstroh
Review

HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective

Lars Peters et al. BMC Infect Dis. 2014.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Anti-HCV antibody prevalence in different EuroSIDA regions
Figure 2
Figure 2
Kaplan Meier progression to liver-related death or hepatic encephalopathy according to baseline plasma hyaluronic acid (HA) level The figure shows the cumulative risk of liver-related death or development of hepatic encephalopathy for patients divided into three different groups according to the HA level (ng/ml) measured in the first available stored plasma sample from each patient. For patients with HA ≤75 ng/ml (the upper limit of normal) the 5-year risk was only 1%, while patients with HA>250 ng/ml the risk was nearly 45%. Among the included patients 67% were anti-HCV positive, the remaining patients had chronic hepatitis B.
Figure 3
Figure 3
Temporal change in Incidence of uptake of HCV treatment among EuroSIDA patients In the period from 1998 -2007 the uptake of HCV treatment increased on average 27% per year (unadjusted incidence rate ratio: 1.27 (95% CI: 1.23 -1.31). From 2007 – 2010 the uptake of HCV decreased 12% per year (unadjusted IRR: 0.88 (95% CI: 0.79 -0.98).
See this image and copyright information in PMC

References

    1. Grint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B. et al.Stability of hepatitis C virus (HCV) RNA levels among interferon-naive HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Med. 2013;14:370–378. - PubMed
    1. Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med. 2013. - PMC - PubMed
    1. Grint D, Peters L, Rockstroh JK, de WS, Mitsura VM, Knysz B. et al.Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. AIDS. 2014;28:577–587. - PubMed
    1. Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, de WS. et al.Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS. 2005;19:2117–2125. - PubMed
    1. Mocroft A, Rockstroh J, Soriano V, Ledergerber B, Kirk O, Vinogradova E. et al.Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Antivir Ther. 2005;10:779–790. - PubMed

Publication types

Substances